Aeras全新数据:结核疫苗可以预防高危青少年患者的持续感染

2018-02-25 MedSci MedSci原创

Aeras是一家在美国马里兰州和南非开普顿均设有办事处的非赢利性生物技术机构,其使命是推进全世界结核病疫苗的发展。近日,Aeras宣布了一项创新性临床试验结果,结果表明结核疫苗可以预防高危青少年患者的持续感染。

Aeras是一家在美国马里兰州和南非开普顿均设有办事处的非赢利性生物技术机构,其使命是推进全世界结核病疫苗的发展。近日,Aeras宣布了一项创新性临床试验结果,结果表明结核疫苗可以预防高危青少年患者的持续感染

在这项于南非进行的以预防感染为目标的II临床试验中,卡介苗(Bacille Calmette-GuerinBCG)的重新接种可降低青少年结核患者的持续性感染的发生。实验性疫苗H4:IC31的重新接种也能够减少持续感染的发生。

开普敦大学南非结核疫苗倡议组织(SATVI)主任Mark Hatherill博士称:“我们很高兴能够完成第一个随机对照的结核病感染预防性临床试验,并证明接种疫苗有可能降低高危环境下持续感染的发病率。尽管这两种疫苗在初始预防结核感染方面都没有统计学意义,但我们对两种疫苗在预防持续性结核感染方面观察到的信号感到极大鼓舞。我们同时期待着测试结核疫苗在未感染青少年中预防结核病的潜力。” 

原始出处:

https://www.europeanpharmaceuticalreview.com/news/72847/tb-vaccine-trial-bcg-revaccination/

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738873, encodeId=8ad71e388735f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jun 10 07:13:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291597, encodeId=08ee29159e43, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Feb 28 07:22:43 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254141, encodeId=367312541416f, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Feb 27 08:13:00 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738873, encodeId=8ad71e388735f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jun 10 07:13:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291597, encodeId=08ee29159e43, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Feb 28 07:22:43 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254141, encodeId=367312541416f, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Feb 27 08:13:00 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-02-28 1dd8c52fm63(暂无匿称)

    了解了解.学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1738873, encodeId=8ad71e388735f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jun 10 07:13:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291597, encodeId=08ee29159e43, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Feb 28 07:22:43 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254141, encodeId=367312541416f, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Feb 27 08:13:00 CST 2018, time=2018-02-27, status=1, ipAttribution=)]

相关资讯

JACS:章晓联团队发表结核疫苗研究重大成果

近期,Journal of the American Chemical Society杂志(JACS,美国化学会志)(影响因子:13.038,SCI 一区)在线发表了武汉大学基础医学院、医学研究院和病毒学国家重点实验室的章晓联课题组的研究成果,武汉大学为唯一署名单位。结核病是目前威胁人类生命健康的三大传染性疾病之一。该病由结核分枝杆菌(也称结核菌,Mycobacterium Tuberculosi